LENZ (LENZ Therapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings
LENZ Therapeutics, Inc. Common Stock (LENZ) is a publicly traded Healthcare sector company. As of May 21, 2026, LENZ trades at $7.18 with a market cap of $216.35M and a P/E ratio of -1.97. LENZ moved +8.50% today. Year to date, LENZ is -56.31%; over the trailing twelve months it is -74.94%. Its 52-week range spans $6.61 to $50.40. Analyst consensus is strong buy with an average price target of $32.20. Rallies surfaces LENZ's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Who owns LENZ stock?
Hedge funds tracked by Rallies that own LENZ include Exoduspoint Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for LENZ Therapeutics, Inc. Common Stock.
LENZ Key Metrics
Key financial metrics for LENZ
Metric
Value
Price
$7.18
Market Cap
$216.35M
P/E Ratio
-1.97
EPS
$-3.64
Dividend Yield
0.00%
52-Week High
$50.40
52-Week Low
$6.61
Volume
1.22K
Avg Volume
0
Revenue (TTM)
$20.99M
Net Income
$-109.00M
Gross Margin
0.00%
Top Hedge Funds Holding LENZ
Exoduspoint Capital holds 57.58K shares of LENZ, changed +148.74% as of Mar 31, 2026.
Hedge funds tracked by Rallies that own LENZ include Exoduspoint Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for LENZ Therapeutics, Inc. Common Stock.
Does Rallies show 13F holders for LENZ?
Yes. Rallies tracks hedge fund and 13F ownership data for LENZ, including fund names, share counts, latest tracked quarter, and position changes when available.
Is LENZ research on Rallies investment advice?
No. Rallies provides research, data, and educational context for LENZ. It does not provide personalized investment advice.
